Literature DB >> 10969818

p53 promotes selection for Fas-mediated apoptotic resistance.

H L Maecker1, C Koumenis, A J Giaccia.   

Abstract

Although p53 inactivation is implicated as a mechanism to explain diminished apoptotic response, it is clear that tumor cells that possess transcriptionally functional p53 can also be resistant to diverse apoptotic stimuli. We hypothesize that oncogenic activation and DNA damage are sufficient stimuli to increase the p53-dependent transcription of Fas and thereby establish a situation in which cell to cell contact could be a selective pressure to either lose p53 function or inactivate components of the Fas death pathway. Examination of genetically matched tumor cell lines that possessed either wild-type or null p53 loci indicated that cells possessing functional p53 increased their surface levels of Fas and Fas ligand (FasL) in response to DNA damage. In contrast, stress induced by changes in the tumor microenvironment such as decreased oxygen did not up-regulate Fas or FasL. Cells with wild-type p53 underwent Fas-mediated killing in the presence of either FasL-expressing killer cells or activating Fas antibodies, whereas cells in which p53 was deleted or inactivated were protected from such killing. Furthermore, Fas and FasL expression and induction became transcriptionally repressed in transformed cells with wild-type p53 with increasing passage, whereas other p53 downstream targets and functions, such as p21 inducibility and cell cycle arrest, remained intact. Repression of the Fas locus could be reverted by treatment with the histone deacetylase inhibitor trichostatin A. These results support a model of tumor progression in which oncogenic transformation drives tumor cells to lose either p53 or their Fas sensitivity as a means of promoting their survival and evade immune surveillance.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10969818

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Yet another function of p53--the switch that determines whether radiation-induced autophagy will be cytoprotective or nonprotective: implications for autophagy inhibition as a therapeutic strategy.

Authors:  Shweta Chakradeo; Khushboo Sharma; Aisha Alhaddad; Duaa Bakhshwin; Ngoc Le; Hisashi Harada; Wataru Nakajima; W Andrew Yeudall; Suzy V Torti; Frank M Torti; David A Gewirtz
Journal:  Mol Pharmacol       Date:  2015-02-09       Impact factor: 4.436

2.  Cardenolide-induced lysosomal membrane permeabilization demonstrates therapeutic benefits in experimental human non-small cell lung cancers.

Authors:  Tatjana Mijatovic; Véronique Mathieu; Jean-François Gaussin; Nancy De Nève; Fabrice Ribaucour; Eric Van Quaquebeke; Patrick Dumont; Francis Darro; Robert Kiss
Journal:  Neoplasia       Date:  2006-05       Impact factor: 5.715

3.  A novel cytostatic form of autophagy in sensitization of non-small cell lung cancer cells to radiation by vitamin D and the vitamin D analog, EB 1089.

Authors:  Khushboo Sharma; Rachel W Goehe; Xu Di; Mark Anthony Hicks; Suzy V Torti; Frank M Torti; Hisashi Harada; David A Gewirtz
Journal:  Autophagy       Date:  2014       Impact factor: 16.016

Review 4.  Apoptosis and traumatic brain injury.

Authors:  Jill Wong; Ng Wai Hoe; Feng Zhiwei; Ivan Ng
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

5.  p53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma.

Authors:  Jong-Lyel Roh; Sung Koo Kang; Il Minn; Joseph A Califano; David Sidransky; Wayne M Koch
Journal:  Oral Oncol       Date:  2010-12-15       Impact factor: 5.337

6.  SUV39H1 regulates human colon carcinoma apoptosis and cell cycle to promote tumor growth.

Authors:  Chunwan Lu; John D Klement; Dafeng Yang; Thomas Albers; Iryna O Lebedyeva; Jennifer L Waller; Kebin Liu
Journal:  Cancer Lett       Date:  2020-02-12       Impact factor: 8.679

7.  Phyllanthus spp. induces selective growth inhibition of PC-3 and MeWo human cancer cells through modulation of cell cycle and induction of apoptosis.

Authors:  Yin-Quan Tang; Indu Bala Jaganath; Shamala Devi Sekaran
Journal:  PLoS One       Date:  2010-09-08       Impact factor: 3.240

8.  Antitumor effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis.

Authors:  Muthu Selvakumaran; Kang Shen Yao; Michael D Feldman; Peter J O'Dwyer
Journal:  Biochem Pharmacol       Date:  2007-10-11       Impact factor: 5.858

9.  PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.

Authors:  Patricia Izetti; Agnes Hautefeuille; Ana Lucia Abujamra; Caroline Brunetto de Farias; Juliana Giacomazzi; Bárbara Alemar; Guido Lenz; Rafael Roesler; Gilberto Schwartsmann; Alessandro Bersch Osvaldt; Pierre Hainaut; Patricia Ashton-Prolla
Journal:  Invest New Drugs       Date:  2014-05-20       Impact factor: 3.850

10.  CD95 is part of a let-7/p53/miR-34 regulatory network.

Authors:  Annika Hau; Paolo Ceppi; Marcus E Peter
Journal:  PLoS One       Date:  2012-11-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.